Genetic aspects of diabetes and its cardiovascular complications: Contribution of genetics to risk assessment and clinical management

Canadian Journal of Cardiology

Volumn 21, Issue 2, 2005, Pages 199-209

  St Pierre, Julie ^a,b   Vohl, Marie Claude ^b   Després, Jean Pierre ^c   Gaudet, Daniel ^a   Poirier, Paul ^a,c  

^a CHICOUTIMI HOSPITAL   (Canada)

^b LAVAL UNIVERSITY   (Canada)

^c LAVAL UNIVERSITY   (Canada)

Author keywords

Cardiovascular diseases; Genetics; Metabolic syndrome; Risk factors; Type II diabetes mellitus

Indexed keywords

ADIPONECTIN; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSINOGEN; ARYLDIALKYLPHOSPHATASE; ATRIAL NATRIURETIC FACTOR; BRADYKININ; CYTOKINE; DIPEPTIDYL CARBOXYPEPTIDASE; ENDOTHELIN 1; FATTY ACID; FATTY ACID BINDING PROTEIN; GELATINASE B; GENE PRODUCT; GLUCAGON RECEPTOR; GLUCOSE TRANSPORTER; GLYCEROL; GLYCOGEN SYNTHASE; GLYCOPROTEIN; INOSITOL TRISPHOSPHATE 3 KINASE; INSULIN RECEPTOR; INSULIN RECEPTOR SUBSTRATE 1; LEPTIN; LIPOPROTEIN LIPASE; LOW DENSITY LIPOPROTEIN; RESISTIN; TRANSCRIPTION FACTOR; TRANSFORMING GROWTH FACTOR BETA; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG;

CARDIOVASCULAR RISK; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DIABETIC ANGIOPATHY; DYSLIPIDEMIA; GENETIC LINKAGE; GENETIC SUSCEPTIBILITY; GLYCEROL BLOOD LEVEL; HIGH RISK PATIENT; HUMAN; HYPERTENSION; HYPERTRIGLYCERIDEMIA; INSULIN RESISTANCE; METABOLIC SYNDROME X; MICROALBUMINURIA; OBESITY; PHENOTYPE; REVIEW; RISK ASSESSMENT; WAIST CIRCUMFERENCE;

ALBUMINURIA; CORONARY ARTERIOSCLEROSIS; DIABETES MELLITUS, TYPE 2; GENETIC PREDISPOSITION TO DISEASE; GLYCEROL; HUMANS; HYPERLIPIDEMIAS; HYPERTENSION; INSULIN RESISTANCE; OBESITY; RISK ASSESSMENT;

EID: 17044424910     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (148)

1. Amos AF, McCarty DJ, Zimmet P. The rising global burden of diabetes and its complications: Estimates and projections to the year 2010. Diabet Med 1997;14(Suppl 5):S1-85.
2. Harris MI, Flegal KM, Cowie CC, et al. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults. The Third National Health and Nutrition Examination Survey, 1988-1994. Diabetes Care 1998;21:518-24.
3. Grundy SM, Benjamin IJ, Burke GL, et al. Diabetes and cardiovascular disease: A statement for healthcare professionals from the American Heart Association. Circulation 1999;100:1134-46.
4. Lee WL, Cheung AM, Cape D, Zinman B. Impact of diabetes on coronary artery disease in women and men: A meta-analysis of prospective studies. Diabetes Care 2000;23:962-8.
5. Gu K, Cowie CC, Harris MI. Diabetes and decline in heart disease mortality in US adults. JAMA 1999;281:1291-7.
6. Executive Summary of the Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.
7. Friesinger GC II, Gavin JA III. Diabetes and the cardiologists: A call to action. J Am Coll Cardiol 2000;35:1130-3.
8. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998; 15:539-53.
9. Poirier F, Després JP. Lipid disorders in diabetes. In: Pickup JC, Williams G, eds. Textbook of Diabetes, 3rd edn. Oxford: Blackwell Publishing, 2002:54.1-54.21.
10. Groop L, Orho-Melander M. The dysmetabolic syndrome. J Intern Med 2001;250:105-20.
11. World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension. Guidelines Subcommittee. J Hypertens 1999;17:151-83.
12. Laaksonen DE, Lakka HM, Niskanen LK, Kaplan GA, Salonen JT, Lakka TA. Metabolic syndrome and development of diabetes mellitus: Application and validation of recently suggested definitions of the metabolic syndrome in a prospective cohort study. Am J Epidemiol 2002;156:1070-7.
13. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143-421.
14. Eckel RH, Krauss RM; AHA Nutrition Committee. American Heart Association call to action: Obesity as a major risk factor for coronary heart disease. Circulation 1998;97:2099-100.
15. Luft FC, Agrawal B. Microalbuminuria as a predictive factor for cardiovascular events. J Cardiovasc Pharmacol 1999;33(Suppl 1):S11-5.
16. Després JP. The insulin resistance-dyslipidemia syndrome: The most prevalent cause of coronary artery disease? CMAJ 1993;148:1339-40.
17. The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med 1997;157:2413-46. (Erratum in 1998;158:573)
18. Isomaa B, Almgren P, Tuomi T, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001;24:683-9.
19. Després JP, Lemieux I, Prud'homme D. Treatment of obesity: Need to focus on high risk abdominally obese patients. BMJ 2001;322:716-20.
20. Koenig W, Sund M, Frohlich M, et al. C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: Results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation 1999;99:237-42.
21. Hak AE, Stehouwer CD, Bots ML, et al. Associations of C-reactive protein with measures of obesity, insulin resistance and subclinical atherosclerosis in healthy, middle-aged women. Arterioscler Thromb Vasc Biol 1999;19:1986-91.
22. Tchernof A, Nolan A, Sites CK, Ades PA, Poehlman ET Weight loss reduces C-reactive protein levels in obese postmenopausal women. Circulation 2002;105:564-9.
23. Lemieux I, Pascot A, Prud'homme D, et al. Elevated C-reactive protein: Another component of the atherothrombotic profile of abdominal obesity. Arterioscler Thromb Vasc Biol 2001;21:961-7.
24. Gervaise N, Garrigue MA, Lasfargues G, Lecomte P. Triglycerides, apo C3 and Lp B: C3 and cardiovascular risk in type II diabetes. Diabetologia 2000;43:703-8.
25. Genest JJ Jr, McNamara JR, Upson B, et al. Prevalence of familial hyperhomocyst(e)inemia in men with premature coronary artery disease. Arterioscler Thromb 1991;11:1129-36.
26. Iso H, Folsom AR, Wu KK, et al. Hemostatic variables in Japanese and Caucasian men. Plasma fibrinogen, factor VIIc, factor VIIIc, and von Willebrand factor and their relations to cardiovascular disease risk factors. Am J Epidemiol 1989;130:925-34.
27. Lobo RA, Notelovitz M, Bernstein L, Khan FY, Ross RK, Paul WL. Lp(a) lipoprotein: Relationship to cardiovascular disease risk factors, exercise, and estrogen. Am J Obstet Gynecol 1992; 166:1182-8.
28. Boemi M, Sirolla C, Amadio L, Fumelli P, Pometta D, James RW. Apolipoprotein E polymorphism as a risk factor for vascular disease in diabetic patients. Diabetes Care 1995;18:504-8.
29. Eaton CB, Bostom AG, Yanek L, et al. Family history and premature coronary heart disease. J Am Board Fam Pract 1996;9:312-8.
30. Assmann G, Cullen P, Schulte H. Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the prospective cardiovascular Munster (PROCAM) study. Circulation 2002;105:310-5.
31. Lindholm LH, Ibsen H, Dahlof B, et al; LIFE Study Group. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol. Lancet 2002;359:1004-10.
32. Hansson L, Zanchetti A, Carruthers SG, et al; HOT Study Group. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998;351:1755-62.
33. Pahor M, Psaty BM, Alderman MH, Applegate WB, Williamson JD, Furberg CD. Therapeutic benefits of ACE inhibitors and other antihypertensive drugs in patients with type 2 diabetes. Diabetes Care 2000;23:888-92.
34. Miller JZ, Weinberger MH, Christian JC, Daugherty SA. Familial resemblance in the blood pressure response to sodium restriction. Am J Epidemiol 1987;126:822-30.
35. Cowley AW Jr. Genetic and nongenetic determinants of salt sensitivity and blood pressure. Am J Clin Nutr 1997;65(2 Suppl):587S-93S.
36. Poch E, Gonzalez D, Giner V, Bragulat E, Coca A, de La Sierra A. Molecular basis of salt sensitivity in human hypertension. Evaluation of renin-angiotensin-aldosterone system gene polymorphisms. Hypertension 2001;38:1204-9.
37. Kinlay S, Libby P, Ganz P. Endothelial function and coronary artery disease. Curr Opin Lipidol 2001;12:383-9.
38. August P, Leventhal B, Suthanthiran M. Hypertension-induced organ damage in African Americans: Transforming growth factor-beta(1) excess as a mechanism for increased prevalence. Curr Hypertens Rep 2000;2:184-91.
39. Corder R, Douthwaite JA, Lees DM, et al. Endothelin-1 synthesis reduced by red wine. Nature 2001;414:863-4.
40. Bragulat E, de la Sierra A. Salt intake, endothelial dysfunction, and salt-sensitive hypertension. J Clin Hypertens 2002;4:41-6.
41. Meeking DR, Cummings MH, Thorne S, et al. Endothelial dysfunction in type 2 diabetic subjects with and without microalbuminuria. Diabet Med 1999;16:841-7.
42. Neugebauer S, Baba T, Watanabe T Association of the nitric oxide synthase gene polymorphism with an increased risk for progression to diabetic nephropathy in type 2 diabetes. Diabetes 2000;49:500-3.
43. Pulkkinen A, Viitanen L, Kareinen A, Lehto S, Vauhkonen I, Laakso M. Intron 4 polymorphism of the endothelial nitric oxide synthase gene is associated with elevated blood pressure in type 2 diabetic patients with coronary heart disease. J Mol Med 2000;78:372-9.
44. Gharavi ALR. The inherited basis of blood pressure variation and hypertension. In: Scriver CR, Beaudet AL, Sly WS, et al, eds. The Metabolic and Molecular Bases of Inherited Disease. New York: McGraw-Hill, 2001:5399-413.
45. Pausova Z, Deslauriers B, Gaudet D, et al. Role of tumor necrosis factor-alpha gene locus in obesity and obesity-associated hypertension in French Canadians. Hypertension 2000;36:14-9.
46. Nicaud V, Raoux S, Poirier O, Cambien F, O'Reilly DS, Tiret L. The TNF alpha/G-308A polymorphism influences insulin sensitivity in offspring of patients with coronary heart disease: The European Atherosclerosis Research Study II. Atherosclerosis 2002;161:317-25.
47. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53. (Erratum in 1999;354:602)
48. Remuzzi G, Schieppati A, Ruggenenti P. Clinical practice. Nephropathy in patients with type 2 diabetes. N Engl J Med 2002;346:1145-51.
49. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851-60.
50. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-9.
51. Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001;345:870-8.
52. Maeda S, Haneda M, Guo B, et al. Dinucleotide repeat polymorphism of matrix metalloproteinase-9 gene is associated with diabetic nephropathy. Kidney Int 2001;60:1428-34.
53. Nannipieri M, Manganiello M, Pezzatini A, De Bellis A, Seghieri G, Ferrannini E. Polymorphisms in the hANP (human atrial natriuretic peptide) gene, albuminuria and hypertension. Hypertension 2001;37:1416-22.
54. Chaves FJ, Pascual JM, Rovira E, Armengod ME, Redon J. Angiotensin II AT1 receptor gene polymorphism and microalbuminuria in essential hypertension. Am J Hypertens 2001;14:364-70.
55. Rodriguez-Perez JC, Rodriguez-Esparragon FJ, Hernandez-Perera O, Fiuza-Perez MD, Anabitarte-Prieto A, Losada-Cabrera A. Effects of the angiotensinogen gene M235T and A(-6)G variants on blood pressure and other vascular risk factors in a Spanish population. J Hum Hypertens 2000;14:789-93.
56. Hegele RA, Harris SB, Hanley AJ, Zinman B. Association between AGT T235 variant and microalbuminuria in Canadian Oji-Cree with type 2 diabetes mellitus. Clin Biochem 1999;32:201-5.
57. Knigge H, Bluthner M, Bruntgens A, Sator H, Ritz E. G(-699)/C polymorphism in the bradykinin-1 receptor gene in patients with renal failure. Nephrol Dial Transplant 2000;15:586-8.
58. Rudberg S, Rasmussen LM, Bangstad HJ, Osterby R. Influence of insertion/deletion polymorphism in the ACE-I gene on the progression of diabetic glomerulopathy in type 1 diabetic patients with microalbuminuria. Diabetes Care 2000;23:544-8.
59. British Diabetic Association. Counting the cost: The real impact of non-insulin-dependent diabetes. London: Kings Fund Policy Institute, 1996.
60. Pan XR, Li GW, Hu YH, et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care 1997;20:537-44.
61. Eriksson KF, Lindgarde F. Prevention of type 2 (non-insulin-dependent) diabetes mellitus by diet and physical exercise. The 6-year Malmo feasibility study. Diabetologia 1991;34:891-8.
62. Tuomilehto J, Lindstrom J, Eriksson JG, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001;344:1343-50.
63. Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393-403.
64. Poirier P, Eckel RH. The heart and obesity. In: Fuster V, Alexander RW, King S, O'Rourke RA, Roberts R, Wellens HJJ, eds. Hurst's The Heart, 10 edn. New York: McGraw-Hill, 2000:2289-303.
65. Umpierrez GE, Isaacs SD, Bazargan N, You X, Thaler LM, Kitabchi AE. Hyperglycemia: An independent marker of in-hospital mortality in patients with undiagnosed diabetes, J Clin Endocrinol Metab 2002;87:978-82.
66. Taylor SI. Diabetes mellitus. In: Scriver CR, Beaudet AL, Sly WS, et al, eds. The Metabolic and Molecular Bases of Inherited Disease. New York: McGraw-Hill, 2001:1433-69.
67. Kahn CR. Banting Lecture. Insulin action, diabetogenes, and the cause of type II diabetes. Diabetes 1994;43:1066-84.
68. Hani EH, Boutin P, Durand E, et al. Missense mutations in the pancreatic islet beta cell inwardly rectifying K+ channel gene (KIR6.2/BIR): A meta-analysis suggests a role in the polygenic basis of Type II diabetes mellitus in Caucasians. Diabetologia 1998;41:1511-5.
69. Huopio H, Otonkoski T, Vauhkonen I, Reimann F, Ashcroft FM, Laakso M. A new subtype of amosomal dominant diabetes attributable to a mutation in the gene for sulfonylurea receptor 1. Lancet 2003;361:301-7.
70. Steppan CM, Lazar MA. Resistin and obesity-associated insulin resistance. Trends Endocrinol Metab 2002;13:18-23.
71. Berg AH, Combs TP, Du X, Brownlee M, Scherer PE. The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat Med 2001;7:947-53.
72. Sentinelli F, Romeo S, Arca M, et al. Human resistin gene, obesity, and type 2 diabetes: Mutation analysis and population study. Diabetes 2002;51:860-2.
73. Shuldiner AR, Yang R, Gong DW. Resistin, obesity and insulin resistance - the emerging role of the adipocyte as an endocrine organ. N Engl J Med 2001;345:1345-6.
74. Mora S, Pessin JE. An adipocentric view of signaling and intracellular trafficking. Diabetes Metab Res Rev 2002;18:345-56.
75. Leyva F, Godsland IF, Ghatei M, et al. Hyperleptinemia as a component of a metabolic syndrome of cardiovascular risk. Arterioscler Thromb Vasc Biol 1998;18:928-33.
76. Berti L, Kellerer M, Capp E, Haring HU. Leptin stimulates glucose transport and glycogen synthesis in C2C12 myotubes: Evidence for a P13-kinase mediated effect. Diabetologia 1997;40:606-9.
77. Muller G, Ertl J, Gerl M, Preibisch G. Leptin impairs metabolic actions of insulin in isolated rat adipocytes. J Biol Chem 1997;272:10585-93.
78. Horikawa Y, Oda N, Cox NJ, et al. Genetic variation in the gene encoding calpain-10 is associated with type 2 diabetes mellitus. Nat Genet 2000;26:163-75.
79. Pouliot MC, Després JP, Lemieux S, et al. Waist circumference and abdominal sagittal diameter: Best simple anthropometric indexes of abdominal visceral adipose tissue accumulation and related cardiovascular risk in men and women. Am J Cardiol 1994;73:460-8.
80. Lakka HM, Lakka TA, Tuomilehto J, Salonen JT. Abdominal obesity is associated with increased risk of acute coronary events in men. Eur Heart J 2002;23:706-13.
81. Lamarche B, Lemieux I, Després JP. The small, dense LDL phenotype and the risk of coronary heart disease: Epidemiology, patho-physiology and therapeutic aspects. Diabetes Metab 1999;25:199-211.
82. Lamarche B, Lemieux S, Dagenais GR, Després JP. Visceral obesity and the risk of ischaemic heart disease: Insights from the Quebec Cardiovascular Study. Growth Horm IGF Res 1998;8(Suppl B):1-8.
83. Rankinen T, Pérusse L, Weisnagel SJ, Snyder EE, Chagnon YC, Bouchard C. The human obesity gene map: The 2001 update. Obes Res 2002;10:196-243.
84. Pérusse L. Genetics of human obesity: Results from genetic epidemiology studies. Ann Endocrinol 2000;61(Suppl 6):24-30.
85. Goldberg RB, Mellies MJ, Sacks FM, et al; The Care Investigators. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: Subgroup analyses in the cholesterol and recurrent events (CARE) trial. Circulation 1998;98:2513-9.
86. Pyorala K, Pedersen TR, Kjekshus J, Faergeman O, Olsson AG, Thorgeirsson G. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 1997;20:614-20.
87. Haffner SM, Alexander CM, Cook TJ, et al. Reduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels: Subgroup analyses in the Scandinavian Simvastatin Survival Study. Arch Intern Med 1999;159:2661-7.
88. Jackson RL. Lipoprotein lipase and hepatic lipases. In: Jackson RL, Boyer P, eds. The enzymes. New York: Academic Press, 1983:141-81.
89. Davignon J, Genest J Jr. Genetics of lipoprotein disorders. Endocrinol Metab Clin North Am 1998;27:521-50.
90. Ukkola O, Garenc C, Pérusse L, et al. Genetic variation at the lipoprotein lipase locus and plasma lipoprotein and insulin levels in the Quebec Family Study. Atherosclerosis 2001;158:199-206.
91. Vohl MC, Lamarche B, Moorjani S, et al. The lipoprotein lipase HindIII polymorphism modulates plasma triglyceride levels in visceral obesity. Arterioscler Thromb Vasc Biol 1995;15:714-20.
92. Minnich A, Baloukas J, Roederer G, Lussier-Cacan S, Davignon J, Genest J Jr. Lipoprotein lipase gene mutations in coronary artery disease. Can J Cardiol 1998;14:711-6.
93. Fisher RM, Humphries SE, Talmud PJ. Common variation in the lipoprotein lipase gene: Effects on plasma lipids and risk of atherosclerosis. Atherosclerosis 1997;135:145-59.
94. Wittrup HH, Tybjaerg-Hansen A, Nordestgaard BG. Lipoprotein lipase mutations, plasma lipids and lipoproteins, and risk of ischemic heart disease. A meta-analysis. Circulation 1999;99:2901-7.
95. Gaudet D, Vohl MC, Perron P, et al. Relationships of abdominal obesity and hyperinsulinemia to angiographically assessed coronary artery disease in men with known mutations in the LDL receptor gene. Circulation 1998;97:871-7.
96. Julien P, Vohl MC, Gaudet D, et al. Hyperinsulinemia and abdominal obesity affect the expression of hypertriglyceridemia in heterozygous familial lipoprotein lipase deficiency. Diabetes 1997;46:2063-8.
97. St-Pierre J, Miller-Felix I, Paradis ME, et al. Visceral obesity attenuates the effect of the hepatic lipase -514C>T polymorphism on plasma HDL-cholesterol levels in French-Canadian men. Mol Genet Metab 2003;78:31-6.
98. St-Pierre J, Lemieux I, Miller-Felix I, et al. Visceral obesity and hyperinsulinemia modulate the impact of the microsomal triglyceride transfer protein -493G/T polymorphism on plasma lipoprotein levels in men. Atherosclerosis 2002;160:317-24.
99. Tall AR. Plasma high density lipoproteins. Metabolism and relationship to atherogenesis. J Clin Invest 1990;86:379-84.
100. Barter PJ, Rye KA. High density lipoproteins and coronary heart disease. Atherosclerosis 1996;121:1-12.
101. Wald NJ, Law M, Watt HC, et al. Apolipoproteins and ischaemic heart disease: Implications for screening. Lancet 1994;343:75-9.
102. Durlach A, Clavel C, Girard-Globa A, Durlach V. Sex-dependent association of a genetic polymorphism of cholesteryl ester transfer protein with high-density lipoprotein cholesterol and macrovascular pathology in type II diabetic patients. J Clin Endocrinol Metab 1999;84:3656-9.
103. Rajappan K, Rimoldi OE, Dutka DP, et al. Mechanisms of coronary microcirculatory dysfunction in patients with aortic stenosis and angiographically normal coronary arteries. Circulation 2002;105:470-6.
104. Murphy GJ, Holder JC. PPAR-gamma agonists: Therapeutic role in diabetes, inflammation and cancer. Trends Pharmacol Sci 2000;21:469-74.
105. Hsueh WA, Jackson S, Law RE. Control of vascular cell proliferation and migration by PPAR-gamma: A new approach to the macrovascular complications of diabetes. Diabetes Care 2001;24:392-7.
106. Vohl MC, Lepage P, Gaudet D, et al. Molecular scanning of the human PPARa gene: Association of the L162v mutation with hyperapobetalipoproteinemia. J Lipid Res 2000;41:945-52.
107. Altshuler D, Hirschhorn JN, Klannemark M, et al. The common PPARgamma Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. Nat Genet 2000;26:76-80.
108. Sanghera DK, Saha N, Aston CE, Kamboh MI. Genetic polymorphism of paraoxonase and the risk of coronary heart disease. Arterioscler Thromb Vasc Biol 1997;17:1067-73.
109. Salonen JT, Malin R, Tuomainen TP, Nyyssonen K, Lakka TA, Lehtimaki T. Polymorphism in high density lipoprotein paraoxonase gene and risk of acute myocardial infarction in men: Prospective nested case-control study. BMJ 1999;319:487-9.
110. Antikainen M, Murtomaki S, Syvanne M, et al. The Gln-Arg191 polymorphism of the human paraoxonase gene (HUMPONA) is not associated with the risk of coronary artery disease in Finns. J Clin Invest 1996;98:883-5.
111. Herrmann SM, Blanc H, Poirier O, et al. The Gln/Arg polymorphism of human paraoxonase (PON 192) is not related to myocardial infarction in the ECTIM Study. Atherosclerosis 1996;126:299-303.
112. Ko YL, Ko YS, Wang SM, et al. The Gln-Arg 191 polymorphism of the human paraoxonase gene is not associated with the risk of coronary artery disease among Chinese in Taiwan. Atherosclerosis 1998;141:259-64.
113. Leviev I, Poirier O, Nicaud V, et al. High expressor paraoxonase PON1 gene promoter polymorphisms are associated with reduced risk of vascular disease in younger coronary patients. Atherosclerosis 2002;161:463-7.
114. Antonarakis SE, Krawczak M, Cooper DN. The nature and mechanisms of human gene mutation. In: Scriver CR, Beaudet AL, Sly WS, et al, eds. The Metabolic and Molecular Bases of Inherited Disease. New York: McGraw-Hill, 2001:343-77.
115. Zraika S, Dunlop M, Proietto J, Andrikopoulos S. Effects of free fatty acids on insulin secretion in obesity. Obes Rev 2002;3:103-12.
116. Boden G. Interaction between free fatty acids and glucose metabolism. Curr Opin Clin Nutr Metab Care 2002;5:545-9.
117. St-Pierre J, Vohl MC, Brisson D, et al. A sequence variation in the mitochondrial glycerol-3-phosphate dehydrogenase gene is associated with increased plasma glycerol and free fatty acid concentrations among French Canadians. Mol Genet Metab 2001;72:209-17.
118. Gaudet D, Arsenault S, Pérusse L, et al. Glycerol as a correlate of impaired glucose tolerance: Dissection of a complex system by use of a simple genetic trait. Am J Hum Genet 2000;66:1558-68.
119. Veerkamp JH, Maatman RG. Cytoplasmic fatty acid-binding proteins: Their structure and genes. Prog Lipid Res 1995;34:17-52.
120. Glatz JF, van der Vusse GJ. Cellular fatty acid-binding proteins: Their function and physiological significance. Prog Lipid Res 1996;35:243-82.
121. Hsu KT, Storch J. Fatty acid transfer from liver and intestinal fatty acid-binding proteins to membranes occurs by different mechanisms. J Biol Chem 1996;271:13317-23.
122. Prochazka M, Lillioja S, Tait JF, et al. Linkage of chromosomal markers on 4q with a putative gene determining maximal insulin action in Pima Indians. Diabetes 1993;42:514-9.
123. Mitchell BD, Kammerer CM, O'Connell P, et al. Evidence for linkage of postchallenge insulin levels with intestinal fatty acidbinding protein (FABP2) in Mexican-Americans. Diabetes 1995;44:1046-53.
124. Berthier MT, Couillard C, Prud'homme D, et al. Effects of the FABP2 A54T mutation on triglyceride metabolism of viscerally obese men. Obes Res 2001;9:668-75.
125. Mansfield MW, Stickland MH, Carter AM, Grant PJ, Polymorphisms of the plasminogen activator inhibitor-1 gene in type 1 and type 2 diabetes, and in patients with diabetic retinopathy. Thromb Haemost 1994;71:731-6.
126. Bastard JP, Pieroni L, Hainque B. Relationship between plasma plasminogen activator inhibitor 1 and insulin resistance. Diabetes Metab Res Rev 2000;16:192-201.
127. Eriksson P, Kallin B, van 't Hooft FM, Bavenholm P, Hamsten A. Allele-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction. Proc Natl Acad Sci USA 1995;92:1851-5.
128. Shimomura I, Funahashi T, Takahashi M, et al. Enhanced expression of PAI-1 in visceral fat: Possible contributor to vascular disease in obesity. Nat Med 1996;2:800-3.
129. Alessi MC, Peiretti F, Morange P, Henry M, Nalbone G, Juhan-Vague I. Production of plasminogen activator inhibitor 1 by human adipose tissue: Possible link between visceral fat accumulation and vascular disease. Diabetes 1997;46:860-7.
130. Gerich JE. The genetic basis of type 2 diabetes mellitus: Impaired insulin secretion versus impaired insulin sensitivity. Endocr Rev 1998;19:491-503.
131. McCarthy MI. Progress in defining the molecular basis of type 2 diabetes mellitus through susceptibility-gene identification. Hum Mol Genet 2004;13 Spec No 1:R33-41.
132. Risch NJ. Searching for genetic determinants in the new millennium. Nature 2000;405:847-56.
133. Brisson D, Vohl MC, St-Pierre J, Hudson TJ, Gaudet D. Glycerol: A neglected variable in metabolic processes? Bioessays 2001;23:534-42.
134. McCabe ERB. Disorders of glycerol metabolism. In: Scriver CR, Beaudet AL, Sly WS, et al, eds. The Metabolic and Molecular Bases of Inherited Disease. New York: McGraw-Hill, 2001:2217-37.
135. Gaudet D. La génétique communautaire dans l'étude des traits complexes: L'exemple de la dyslipidémie hypertensive. Méd Sci 2000;16:9.
136. St-Pierre J, Brisson D, Larochelle P, Tremblay J, Gaudet D. La glycérolémie à jeun explique une proportion significative de la variance dans la distribution de la masse corporelle dans des familles hypertendues du Saguenay-Lac-St-Jean. Méd Sci 2000;16:21.
137. Damiano PF, Roson MI, Armando I, et al. Potential role of glycerol leading to rat fructose hypertension. Hypertension 1999;34:1007-11.
138. Guan HP, Li Y, Jensen MV, Newgard CB, Steppan CM, Lazar MA. A futile metabolic cycle activated in adipocytes by antidiabetic agents. Nat Med 2002;8:1122-8.
139. Lamarche B, Tchernof A, Moorjani S, et al. Small, dense lowd-ensity lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Prospective results from the Quebec Cardiovascular Study. Circulation 1997;95:69-75.
140. Pouliot MC, Després JP, Nadeau A, et al. Visceral obesity in men. Associations with glucose tolerance, plasma insulin, and lipoprotein levels. Diabetes 1992;41:826-34.
141. Tchernof A, Lamarche B, Prud'Homme D, et al. The dense LDL phenotype. Association with plasma lipoprotein levels, visceral obesity, and hyperinsulinemia in men. Diabetes Care 1996;19:629-37.
142. Lemieux I, Pascot A, Couillard C, et al. Hypertriglyceridemic waist: A marker of the atherogenic metabolic triad (hyperinsulinemia; hyperapolipoprotein B; small, dense LDL) in men? Circulation 2000;102:179-84.
143. St-Pierre J, Lemieux I, Vohl MC, et al. Contribution of abdominal obesity and hypertriglyceridemia to impaired fasting glucose and coronary artery disease. Am J Cardiol 2002;90:15-8.
144. Lemieux I, Almeras N, Mauriège P, et al. Prevalence of 'hypertriglyceridemic waist' in men who participated in the Quebec Health Survey: Association with atherogenic and diabetogenic metabolic risk factors. Can J Cardiol 2002;18:725-32.
145. Lamarche B, Tchernof A, Mauriège P, et al. Fasting insulin and apolipoprotein B levels and low-density lipoprotein particle size as risk factors for ischemic heart disease. JAMA 1998;279:1955-61.
146. St-Pierre J, Brisson D, Perron P, Després JP, Gaudet D. Impact de la mutation N288D du gène de la glycérol kinase sur l'expression phénotypique de l'hypercholestérolémie familiale résultant de la mutation W66G du gène du récepteur des LDL: Un modèle d'interaction génétique associée à la triade métabolique (hyperapo B, hyperinsulinémie, LDL denses). Méd Sci 2001;17:xx.
147. Maitland-van der Zee AH, Klungel OH, Stricker BH, et al. Genetic polymorphisms: Importance for response to HMG-CoA reductase inhibitors. Atherosclerosis 2002;163:213-22.
148. Brisson D, Ledoux K, Bossé Y, et al. Effect of apolipoprotein E, peroxisome proliferator-activated receptor alpha and lipoprotein lipase gene mutations on the ability of fenofibrate to improve lipid profiles and reach clinical guideline targets among hypertriglyceridemic patients. Pharmacogenetics 2002;12:313-20.